Background and purpose: We aimed to assess the prescription preference about hypofractionated radiation therapy (HFRT) for breast cancer (BC) patients amongst radiation oncologists (ROs) practicing in Europe and to identify restraints on HFRT utilisation. Materials and methods: An online survey was circulated amongst ROs in Europe through personal, RO and BC societies' networks, from October 2019 to March 2020. The statistical analyses included descriptive statistics, chi-squared testing, and logistic regression analysis. Results: We received 412 responses from 44 countries. HFRT was chosen as the preferred schedule for whole breast irradiation (WBI) by 54.7% and for WBI with regional nodes irradiation (RNI) by 28.7% of the responding ROs. In the case of postmastectomy RT with or without reconstruction, HFRT was preferred by 21.1% and 29.6%, respectively. Overall, 69.2% of the responding ROs selected at least one factor influencing the decision to utilise HFRT, the most frequent of which included age (51.4%), RNI (46.9%), internal mammary lymph nodes irradiation (39.7%), BC stage (33.5%) and implant-based breast reconstruction (31.6%). ROs working in academic centres (odds ratio, (OR), 1.7; 95% confidence interval, (CI); 1.1-2.6, p = 0.019), practicing in Western Europe (OR, 4.2; 95%CI; 2.7-6.6, p < 0.0005) and/or dedicating >50% of clinical time to BC patients (OR, 2.5; 95%CI; 1.5-4.2, p = 0.001) more likely preferred HFRT. Conclusion: Although HFRT is recognised as a new standard, its implementation in routine RT clinical practice across Europe varies for numerous reasons. Better dissemination of evidence-based recommendations is advised to improve the level of awareness about this clinical indication.

No abstract

She was principal investigator in 49 international and 10 national studies, the author of 146 specialized articles and 14 books or book chapters and has participated as the invited speaker at over 200 national and international conferences. It is also worth mentioning the fact that she graduated with a Master's degree in Public Administration at the National School of Political and Administrative Studies. As a result of her work, she has been awarded distinctions and awards from the American Cancer Society, the Romanian Academy of Scientists, the Federation of Cancer Patient Associations and the National Association for Patient Protection.You are a very active person, involved in many activities, including organizational.

on clinical oncology, multidisciplinary approach of cancer, radiation dosimetry, radiobiology, medical informatics and evaluation of the quality of the medical act in the oncology services and radiotherapy. The results of his research can be found in numerous scientific papers, published nationally and abroad.

Professor Marcel van Herk is the chair of the radiotherapy physics at the University of Manchester. As a medical physics student he started on the development of a liquid ionization imaging device that later became the Varian PortalVision system for electronic portal imaging. Starting during a Postdoc at Harvard Medical School, USA in 1992, his work incorporated 3D image processing, first CT-MR image registration for treatment planning, later measuring organ motion and other uncertainties in radiotherapy such as delineation variability. Much of this work has been integrated in the Elekta Synergy cone-beam CT image guidance system developed. He also held a part-time teaching role as a Professor at the University of Amsterdam working amongst others at the integration of microscopic optical imaging into radiotherapy treatment planning. His goal is to do research to improve the clinical practice of radiotherapy.